Placental Tissue Amendments

SB 55 requires health care providers who offer stem cell therapies not approved by the U.S. Food and Drug Administration (FDA) to provide patients with a specific written notice. This notice, written in 40-point type on standard paper, must state that the therapy is unapproved and encourage patients to consult their primary care provider. The bill also mandates that providers display this notice prominently in their offices, include it in advertisements, and obtain a signed consent form detailing the therapy's FDA status, risks, and alternatives. It directly affects providers using placental-derived or other unapproved stem cell therapies, excluding those with FDA investigational approval or working under specific accredited institutions. The law takes effect in May 2026.